Drugs / lonigutamab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05683496 | Feb 2023 → May 2025 | endocrine exophthalmos | ACELYRIN Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lonigutamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05683496 ↗ |
| Known as | VB-421 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314990 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314990 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT05683496 ↗ |